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Abstract
Background—Additional medications are needed for inflammatory bowel disease (IBD), as
existing therapies are incompletely effective and can be costly and toxic. Preclinical studies
suggest that topiramate (an anticonvulsant) may have disease-modifying properties in IBD, but its
efficacy in humans is unknown.
Aim—To evaluate whether topiramate use is associated with clinical benefit in IBD patients.
Methods—We conducted a retrospective cohort study using administrative claims data from the
MarketScan databases. Persons with IBD were identified between 2000 and 2010. New users of
topiramate were compared with users of other anticonvulsant and anti-migraine medications. The
primary outcome was a new prescription for an oral steroid (≥14 days). Secondary outcomes
included initiation of biologic agents, abdominal surgery, and hospitalization. Cox proportional
hazard modeling was used to adjust for potential confounders.
Results—We identified 773 new users of topiramate and 956 users of comparator drugs. After
adjusting for potential confounders, topiramate use was not associated with the primary outcome
of steroid prescriptions (HR 1.14, 95% CI 0.74, 1.73). Results did not differ significantly by IBD
subtype. There was no difference between topiramate users and users of comparator drugs with
respect to post-exposure initiation of biologic agents (HR 0.93, 95% CI 0.35, 2.52), abdominal
surgery (HR 1.22, 95% CI 0.70, 2.12), or hospitalization (HR 0.78, 95% CI 0.49, 1.26).
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Conclusion—In this large US administrative claims study, topiramate use was not associated
with markers of IBD flares. These results cast doubt on whether topiramate may be an effective
adjunct to current IBD therapy.
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INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic condition that affects over a million
Americans[1,2] and is associated with substantial morbidity, including frequent
hospitalization and surgery [3], reductions in quality of life [4], and increased mortality [5].
Contemporary studies show that IBD is associated with significant healthcare expenditures,
with estimated annual direct costs of over $6 billion in the US alone [6]. Current medical
therapies for ulcerative colitis (UC) and Crohn's disease (CD) include drugs that are only
modestly effective, have serious potential toxicities, are challenging to administer, or are
very costly. Pharmacoepidemiology studies that explore novel uses of existing medications
could lead to the identification of safe and inexpensive treatment options for patients with
IBD. This “drug repositioning [7]” approach is particularly appealing for uncommon
diseases like IBD, where traditional drug development approaches may not be as attractive
for the pharmaceutical industry [8].
There are currently over 6,000 FDA-approved medications available in the US. The concept
of drug repositioning involves identifying currently approved medications (regardless of
indication) that may be useful for other disease processes. Given the substantial cost and
time investment associated with de novo drug development, this concept has become
attractive for industry, researchers, clinicians, and patients alike. Successful, high profile
examples of drug repositioning include use of aspirin for prevention of cardiovascular
disease [9], sildenafil for erectile dysfunction and pulmonary hypertension [10], thalidomide
for multiple myeloma [11], and angiotensin II receptor blockers for Marfan's syndrome [12].
Uncommon diseases that are associated with high morbidity such as IBD are ideal
candidates for drug repositioning research.
Topiramate (Topamax), an FDA-approved medication used primarily for seizure
prophylaxis, was identified as a possible IBD treatment in a recent high profile study [13].
Using the Connectivity Map, Dudley et al. compared the gene expression signatures of a
compendium of 164 drug compounds to that of IBD, and found that topiramate was
associated with the strongest “therapeutic score” for both UC and CD, on par with
prednisolone, an established IBD therapy. Furthermore, topiramate performed favorably in a
preclinical rodent colitis model. However, the efficacy of topiramate in humans with IBD is
uncertain and has not been studied previously. We aimed to conduct a
pharmacoepidemiology study using administrative data to determine whether topiramate
exposure is associated with a reduced rate of disease flares in subjects with IBD.
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Study design and data source
We conducted a retrospective cohort study using claims data from the MarketScan®
databases (Truven Health Analytics Inc.). These US databases contain over 500 million
claims on roughly 100 million individuals covered by employer-sponsored commercial
health insurance from approximately 100 payers, including health plans, large employers,
government and public organizations. Data elements include inpatient and outpatient
diagnoses [International Classification of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) codes], procedures [Current Procedural Terminology, 4th Edition (CPT)
codes], prescription records, demographic information, and enrollment details. Data from
January 2000 to December 2010 were used in this study. This database has been used in
other epidemiologic studies of IBD [14] and anticonvulsants [15], and is representative of
the commercially-insured population of the US [16].
Cohort identification and assessment of exposures
We selected IBD patients initiating topiramate therapy and a comparator group of IBD
patients using other anticonvulsant and antimigraine drugs. First, the entire source
population (n=104,951,068) was limited to those who met the IBD case definition: 1) at
least 1 healthcare contact associated with an ICD-9-CM diagnosis code for CD (555.xx) or
UC (556.xx) and 2) at least 1 pharmacy claim for any of the following IBD medications:
mesalamine, olsalazine, balsalazide, sulfasalazine, 6-mercaptopurine, azathioprine,
infliximab, adalimumab, certolizumab, natalizumab or enteral budesonide. To qualify for the
study, exposed subjects had a new prescription (minimum 30 days supplied) for either
topiramate, or one of the following comparator drugs: levetiracetam, phenytoin, lamotrigine,
carbamazepine, oxcarbamazepine, valproate, or propranolol. This “active comparator, new
user design” was used to minimize bias resulting from analysis of prevalent medication use
compared with non-use such as the healthy user effect [17].
During a 6 month period prior to initiation of topiramate or a comparator drug, exclusion
criteria were applied. Subjects were excluded if they did not meet the IBD diagnostic
criteria. Other exclusion criteria included pre-exposure use of oral steroids (within 3 months
of exposure), combination therapy with anticonvulsants, colectomy (for UC patients), and
diagnoses of colorectal cancer, brain tumors, and esophageal varices. Subjects were also
excluded if they did not have continuous health plan enrollment and pharmacy benefits
during the 6 month pre-exposure period and the first month after drug exposure.
Assessment of covariates of interest
In addition to demographic information on age, sex, and geographic region (Northeast,
North Central, South, and West based on US Census regions), data on potential confounders
were measured based on claims during the 6 month pre-exposure period. These covariates
included type of IBD (CD or UC, based on majority of diagnosis claims), use of other IBD
medications [aminosalicylate drugs (mesalamine, olsalazine, balsalazide, sulfasalazine), 6-
mercaptopurine (6-MP) or azathioprine, biologic agents (infliximab, adalimumab,
certolizumab, and natalizumab), rectal steroids (enema, suppository, or foam), methotrexate,
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or cyclosporine], markers of disease severity [weight loss (ICD-9 783.2), malnutrition
(ICD-9 262.xx - 263.xx) and anemia (ICD-9 280.xx)], diagnosis of concomitant irritable
bowel syndrome (IBS) (ICD-9 564.1), non-colectomy abdominal surgery (CPT
44500-44979, 49000-49999, 45000-45190, 45395-45999, 46020-46211, 46270-46288,
46700-46762, 46937-46942, 46999), comorbidities (Deyo modification of the Charlson
comorbidity index [18]), claims for prescribing indications [seizure disorder (ICD-9 345.xx,
780.3, 781.0), migraine headaches (ICD-9 346.xx), bipolar disorder (ICD-9 296.xx), obesity
(ICD-9 278.0), and peripheral neuropathy (ICD-9 337.0-1, 356.xx, 357.xx)], and markers of
healthcare utilization [number of prescriptions, outpatient contacts, hospitalizations, and
endoscopic procedures (upper or lower endoscopy, CPT codes: 43200-43259, 44360-44386,
44388-44397, or 45300-45392)].
Follow-up and outcomes
Participants were censored if they experienced a lapse in plan enrollment/pharmacy benefit
> 1 month, if they stopped using topiramate or comparator drug (defined as a gap of >60
days beyond days supplied, according to a previously published definition [19]), or if they
reached the end of study period (December 31, 2010). Subjects were censored at age 65 in
conjunction with enrollment lapse and transition to Medicare.
The primary outcome for this study was defined as a 1st prescription for an oral steroid (days
supplied ≥ 14), a marker of flare of disease [20]. Secondary outcomes included a 1) 1st use
of any biologic agent (if not used in 6 months pre-exposure); 2) colectomy or other
abdominal surgery (if no surgery 6 months prior to drug exposure, and excluding outpatient
anal procedures such as hemorrhoidectomy); 3) first hospitalization, and 4) a composite
outcome (i.e. any primary or secondary outcome).
Statistical Analysis
Sample size—Our sample size was not pre-specified, as we planned to include all subjects
meeting the inclusion and exclusion criteria outlined above.
Bivariate analysis—Bivariate analysis was performed between covariates and the
exposure (using chi-squared tests for categorical variables, or Student's t-tests for continuous
variables), and the primary outcome (using Kaplan Meier plots and log rank tests).
Covariates were evaluated for confounding and effect modification if they were significantly
associated with the exposure and outcome at an alpha of ≤ 0.2, or if they were believed to be
important confounders based on previously published data.
Survival and Multivariate analysis—Prior to inclusion in modeling, each variable was
evaluated with log-log plots to ensure the proportional hazards assumption was not violated.
First, Kaplan Meier plots were created for each outcome, without adjustment for covariates.
Subsequently, Cox proportional hazard modeling was performed to estimate adjusted hazard
ratios (aHR) for the association between topiramate use and the primary and secondary
outcomes. To determine which covariates to include in the final multivariable models, a full
model with all potential confounders was constructed. Covariates were then removed from
the model using backwards elimination with a threshold of <10% change in beta coefficients
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and a likelihood ratio test p value of >0.05. Because this process was repeated iteratively for
each outcome, the adjustment set differed slightly for models for the primary and secondary
outcomes. All analyses were performed with STATA version 10.1 (College Station, TX).
Dosage, duration, and adherence analyses—To assess the possible contribution of
dose, initial topiramate dose was categorized into ≤ 50mg/day and ≥100mg/day dose.
Duration of topiramate therapy was dichotomized as ≤60 days vs. >60 days. In addition, the
medication possession ratio [MPR calculated as: (sum of days supplied) ÷ (days of follow-
up)] was categorized using cutoff of 0.90 to determine whether different levels of adherence
modified the effect of topiramate use [21].
Sub-analyses—A number of secondary analyses were conducted to further evaluate our
findings, including stratifying by gender and age (≤40 vs. >40 years), and restricting the
population to: subjects with a diagnosis claim for seizure disorder, migraine headaches, or
bipolar disorder. We also performed pairwise comparisons to analyze users of topiramate
compared to each individual comparator drug.
Ethical considerations: The study protocol was granted an exemption by the Institutional




Out of a total of 230,654 subjects with at least 1 IBD diagnosis and drug claim, we identified
775 topiramate exposed subjects and 958 subjects exposed to comparator drugs (Figure 1).
Characteristics of each group are shown in Table 1. The mean age was similar in both
groups (42 ± 12 for topiramate initiators, and 41 ± 14 for initiators of comparator drugs).
Women represented a higher proportion of topiramate users (79% vs. 59%). IBD subtype
did not differ between groups. With respect to indications for the drugs of interest, there was
a higher proportion of topiramate users with migraine diagnoses (37 vs. 9%), and lower
proportion with diagnoses of seizures or bipolar disorder (5 vs. 12% and 12 vs. 24%
respectively). Mean Charlson comorbidity index scores were similar (0.45 ± 0.85 vs. 0.44 ±
1.01). IBD medication use in the pre-exposure period was similar between groups, though a
slightly higher proportion of topiramate users were exposed to biologic agents (15 vs. 12%).
In terms of healthcare utilization, topiramate users were less commonly hospitalized (17 vs.
25%), but had more outpatient contacts and prescriptions compared to users of comparator
drugs (means 15 ± 11 vs. 13 ± 10 and 17 ± 11 vs. 13 ± 8, respectively).
Primary outcome
Over a median follow-up of 2.8 months, 115 patients filled a prescription for an oral steroid
(primary outcome) for an overall incidence rate of 14 per 100 person years. The unadjusted
Kaplan Meier survival was similar between groups (p=0.78) (Figure 2). Cox proportional
hazards modeling revealed no significant difference between groups with respect to the
primary outcome after adjustment for age, sex, region, pre-exposure diagnosis of seizures,
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migraines, bipolar disorder, use of biologic agents, enteral budesonide, and number of
prescriptions [aHR 1.14 (0.74, 1.73)] (Table 2). Stratification by disease subtype revealed
similar findings [UC: aHR 1.06 (0.53, 2.13); Crohn's: aHR 1.23 (0.71, 2.11)].
Secondary outcomes
For initiation of anti-TNF therapy, abdominal surgery, hospitalization, and the composite
outcome (any primary or secondary outcome), there was no difference in unadjusted
survival (i.e. time until outcome occurrence) comparing topiramate users to the comparator
group (Figure 3). Similarly, Cox proportional hazards modeling did not reveal any
significant differences in the hazard of these outcomes comparing topiramate and
comparator drug groups (Table 2).
Sub-analyses and dose response
Results of subanalyses are shown in Table 3. Stratification by age or gender did not change
our results substantially. HR estimates tended to decrease with increasing dose, duration of
use, and adherence to topiramate, but remained >1 and were not statistically significant. To
investigate whether topiramate may act differently depending on the indication for its use,
we examined whether limiting the population to those with a diagnosis of seizure disorder,
migraine headache, or bipolar disorder changed the results, and it did not. Because IBD
patients with concomitant irritable bowel syndrome may be more likely to be prescribed
topiramate and may experience flares differently, we examined the effect of excluding
subjects with a diagnosis of IBS and found no difference.
Pairwise comparisons
Because our comparator group included subjects exposed to a number of different
medications which may have introduced heterogeneity, we examined the effect of varying
the comparator group composition on our results. Results of pairwise comparisons of
anticonvulsant and antimigraine drugs are shown in Table 3. For the most part, HR estimates
were similar and not statistically significant, though comparison with levetiracetam yielded
an elevated (but not statistically significant) HR estimate of 3.64 (0.93, 14.3).
DISCUSSION
In this retrospective cohort study, we found no evidence of a therapeutic benefit of
topiramate in patients with IBD. We did not find evidence of differential efficacy (or lack
thereof) based on gender, age, dose, duration of use, adherence, disease subtype,
comorbidities or variations in the comparator group. This was an unequivocal negative
study.
Drug repositioning is an important and burgeoning genre of pharmacoepidemiology
research, and is particularly appealing for uncommon diseases such as IBD. The impetus for
our research was a recent study in which topiramate was identified as an intriguing IBD
therapeutic candidate based on its gene expression profile and pre-clinical data [13]. In light
of this promising report, the lack of a demonstrable effect of topiramate in our study is
disappointing. Nevertheless, we feel that this study illustrates the importance and feasibility
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of using existing data to rapidly evaluate the potential effectiveness of promising drug
repositioning candidates in order to identify those agents that merit further clinical
investigation.
The strengths of this study bear mentioning. First, the size of the database allowed us to
identify a large enough population of topiramate-exposed IBD patients to provide reasonable
enough confidence that the negative findings observed here were not due to inadequate
power or sample size. Indeed, the lower limit of the 95% confidence interval is compatible
with a 25% reduction in the hazard of an IBD flare. While a weaker effect could
theoretically exist, its clinical significance would be arguable. Importantly, most of our HR
point estimates were greater than 1. Second, we used established administrative definitions
for IBD and markers of flares, and assessed a number of different relevant outcomes.
Additionally, we would expect high fidelity of drug exposure and primary outcome
information (i.e. prescriptions filled, picked up, and paid for). Finally, we used an “active
comparator, new user design” which is more methodologically sound comparing prevalent
users of drugs with non-users.
In designing this study, we considered several possible “control” groups including all IBD
subjects unexposed to topiramate and a control group of IBD subjects matched via
propensity scores, but determined that a comparator group composed of users of peer
medications would result in groups that were matched most closely with each other, apart
from the specific drug exposures of interest. Adjusting for remaining differences between
exposed and unexposed patients using multivariable modeling did not change the lack of
association seen in this study. This is, in essence, a comparative effectiveness study. While it
may not be typical for IBD patients to be prescribed anticonvulsants, we found that when
they were, there was no difference in flares when they were prescribed topiramate vs. other
agents. We therefore feel that these data provide good evidence that topiramate use among
IBD patients is unlikely to be a highly effective disease-modifying agent. Nonetheless, it is
possible that our comparator group selection led to some unforeseen bias, and unmeasured
or residual confounding is always possible.
There are additional limitations associated with using administrative claims data that we
attempted to address with our study design. As with any study using claims data, there exists
the possibility of misclassification bias. In order to minimize misclassification of the study
population, we used a previously reported administrative claims definition for IBD that is
similar or more rigorous that others that have been reported or validated elsewhere [2,22].
The exposure and primary outcome were measured by prescriptions filled vs. patient report,
which would be expected to minimize misclassification, but it is possible that some people
who were prescribed topiramate actually did not take it, or took it only briefly. However, we
found that even prolonged use and high adherence to topiramate were unassociated with
reduced markers of disease flares. Given the lack of available clinical detail, we were unable
to examine the potentially important effects of smoking history, disease phenotype, or use of
non-prescription drugs such as over the counter analgesics, probiotics, fiber, etc. We also
recognize that initiation of steroids may not be a perfect marker of flares of IBD, and it is
possible that some steroid use in this population was related to non-IBD indications.
However, even in absence of a 100% correlation with flare of disease, steroid use is an
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important clinical outcome in itself given the associated toxicities of glucocorticoid therapy.
Furthermore, follow-up may not have been long enough to capture all secondary outcome
events (e.g. initiation of biologic agents), which could have biased these analyses toward the
null. Regarding generalizability, we believe these results are applicable to commercially-
insured patients in the US, but possibly not to other populations (e.g. elderly, uninsured,
other nationalities). Lastly, data from this single study do not preclude the possibility that
topiramate may be useful in aborting flares of IBD or in achieving other outcomes not
studied here.
In summary, despite promise based on in silico and pre-clinical data, in this administrative
claims study we found no evidence of a beneficial effect of topiramate in inflammatory
bowel disease. This study highlights the important role of pharmacoepidemiology studies in
drug repositioning research; shortly after topiramate was identified as a possible IBD
therapy candidate, we were able to assess the potential efficacy of this agent using existing
“real world” data from IBD patients taking this medication. While additional studies will be
needed to confirm these results, our findings do not suggest that topiramate is likely to be a
highly effective IBD therapy.
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Flow diagram for identification of study population.
IBD Dx: ICD-9 CM diagnosis code for an inflammatory bowel disease; IBD Rx:
prescription for IBD specific medication (see text for details).
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Kaplan-Meier survival graph for primary outcome (steroid prescription ≥14 days)
comparing new users of topiramate (black line) and comparator drugs (gray line).(p=0.78)
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Kaplan Meier graphs for secondary outcomes including (A) initiation of biologic agents, (B)
abdominal surgery, (C) hospitalization, (D) composite outcome (any primary or secondary
outcome) comparing new users of topiramate (black lines) and comparator drugs (gray
lines).
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Table 1
Characteristics of cohort based on claims in 6 month pre-exposure period
Characteristics Topiramate (n = 775) n (%) or mean
± SD




Topiramate 775 (100) 0 (0)
Levetiracetam 0 (0) 61 (6)
Phenytoin 0 (0) 47 (5)
Carbamazepine/oxcarbazepine 0 (0) 77 (8)
Lamotrigine 0 (0) 255 (27)
Valproic Acid 0 (0) 127 (13)
Propranolol 0 (0) 391 (41)
Age 0-20 41 (5) 78 (8) 0.07
21-40 309 (40) 368 (38)
41-64 425 (55) 512 (53)
Sex Female 615 (79) 563 (59) <0.001
Male 160 (21) 395 (41)
Region Northeast 89 (11) 138 (14) <0.001
North Central 187 (24) 305 (32)
South 382 (49) 380 (40)
West 115 (15) 132 (14)
IBD type 1.0
Crohn's 428 (55) 527 (55)
UC 337 (43) 418 (44)
Indeterminate 10 (1) 13 (1)
Comorbidities
Seizure diagnosis 40 (5) 114 (12) <0.001
Migraine 284 (37) 88 (9) <0.001
Bipolar disorder 91 (12) 230 (24) <0.001
Obesity 20 (3) 12 (1) 0.04
Peripheral neuropathy 23 (3) 8 (1) 0.001
Congenital brain abnormality 2 (0.3) 2 (0.2) 0.8
IBS 48 (6) 51 (5) 0.4
Weight loss 9 (1) 21 (2) 0.1
Malnutrition 6 (<1) 9 (<1) 0.7
Anemia 39 (5) 54 (6) 0.6
Charlson index† 0.45 ± 0.85 0.44 ± 1.01 0.7
IBD drugs






















Crockett et al. Page 15
Characteristics Topiramate (n = 775) n (%) or mean
± SD
Comparator group (n = 958) n (%) or
mean ± SD
p value*
5-ASA‡ 563 (73) 721 (75) 0.2
6MP/AZA 219 (28) 268 (28) 0.9
Methotrexate 20 (3) 18 (2) 0.3
Cyclosporine 6 (<1) 3 (<1) 0.2
Enteral budesonide 103 (13) 109 (11) 0.2
Rectal steroid 36 (5) 47 (5) 0.8
Any biologic 166 (21) 166 (17) 0.03
    Infliximab 115 (15) 117 (12) 0.1
    Adalimumab 46 (6) 46 (5) 0.3
    Certolizumab 5 (<1) 8 (<1) 0.8
    Natalizumab 3 (<1) 1 (<1) 0.2
Healthcare utilization
Any hospitalization 131 (17) 242 (25) <0.001
Outpatient visits 15 +/− 11 13 +/−10 <0.001
Number of Rx 17 +/− 11 13 +/− 8 <0.001
Endoscopy
EGD 99 (13) 106 (11) 0.3
Colonoscopy 237 (31) 276 (29) 0.4
Any endoscopy 291 (38) 345 (36) 0.5
*
p values obtained via Chi-squared tests or Student's t-tests
†
Deyo modification of Charlson comorbidity index
‡
5-ASA includes prescription for sulfasalazine, mesalamine, olsalazine, or balsalazide
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Table 2
Cox proportional hazards model estimates for primary and secondary outcomes, overall and stratified by
disease subtype.
Estimates












    all IBD 1.05 (0.73, 1.52) 1.23 (0.61, 2.49) 1.33 (0.27, 6.61) 0.83 (0.63, 1.10) 0.86 (0.66, 1.13)
    Crohn's 1.26 (0.78, 2.04) 1.26 (0.56, 2.87) 1.37 (0.28, 6.80) 0.82 (0.57, 1.17) 0.80 (0.55, 1.18)
    UC 0.81 (0.45, 1.46) 1.22 (0.31, 4.89) NE 0.78 (0.49, 1.26) 0.89 (0.61, 1.32)
Adjusted HR
*
    all IBD 1.14 (0.74, 1.73) 0.93 (0.39, 2.19) 1.04 (0.17, 6.41) 0.86 (0.62, 1.19) 0.96 (0.71, 1.31)
    Crohn's 1.23 (0.71, 2.11) 0.94 (0.35, 2.52) 1.20 (0.20, 7.09) 0.81 (0.54, 1.20) 0.82 (0.53, 1.26)
    UC 1.06 (0.53, 2.13) 1.18 (0.22, 6.39) NE 0.93 (0.52, 1.65) 1.16 (0.73, 1.85)
HR: Hazard ratio; IBD: Inflammatory bowel disease; UC: ulcerative colitis; NE: No estimate (e.g. too few events)
*
Adjusted for age, sex, region, and pre-exposure dx of seizure, migraine, bipolar disorder, use of enteral budesonide, use of biologic agents (except
for this outcome), and number of prescriptions in pre-exposure period.
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Table 3
Subanalyses for primary outcome examining effects of gender and age, dose response, and variations in study
population and comparator group.
Subanalysis Steroid prescription aHR* (95% CI)
Gender
    Males only 1.37 (0.65, 2.90)
    Females only 1.18 (0.70, 1.99)
Age
    0-40 years 1.20 (0.66, 2.19)
    >40 years 1.09 (0.60, 1.99)
Study population
    Limit to seizure diagnosis 2.64 (0.83, 8.38)
    Limit to migraine diagnosis 1.78 (0.58, 5.54)
    Limit to bipolar diagnosis 1.31 (0.46, 3.67)
    Exclude diagnosis IBS 1.18 (0.77, 1.82)
Dose response
    Dosage: 15-50mg/day 1.14 (0.74, 1.76)
        100-200mg/day 1.04 (0.40, 2.68)
    Duration: ≤60 days 1.33 (0.61, 2.89)
        >60 days 1.10 (0.70, 1.71)
    Adherence: MPR <90% 1.24 (0.71, 2.15)
        MPR ≥90% 1.08 (0.68, 1.73)
Pairwise comparisons
    Topiramate vs. all 1.14 (0.74, 1.73)
    vs. all AEDs† 1.20 (0.71, 2.01)
    vs. Levetiracetam 3.64 (0.93, 14.3)
    vs. Phenytoin 0.91 (0.27, 3.10)
    vs. Carbamazepine‡ 1.05 (0.41, 2.70)
    vs. Lamotrigine 1.38 (0.71, 2.67)
    vs. Valproate 1.57 (0.61, 4.02)
    vs. Propranolol 0.97 (0.57, 1.63)
IBS: irritable bowel syndrome; MPR: medication possession ratio = (total days supplied)/(days in study); AED: anti-epileptic drugs
*
Hazard ratio for all inflammatory bowel disease subjects, adjusted for age, sex, region, and pre-exposure dx of seizure, migraine, bipolar disorder,
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